Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States.

Détails

ID Serval
serval:BIB_9623F2827944
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States.
Périodique
Journal of child and adolescent psychopharmacology
Auteur⸱e⸱s
Smogur M., Onesanu A., Plessen K.J., Eap C.B., Ansermot N.
ISSN
1557-8992 (Electronic)
ISSN-L
1044-5463
Statut éditorial
Publié
Date de publication
03/2022
Peer-reviewed
Oui
Volume
32
Numéro
2
Pages
80-88
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Objectives: The decision to prescribe a medication and the choice of which one are often complex, particularly in the field of child and adolescent psychiatry where evidence is scarce. The aim of this review is to provide a synthesis of psychotropic drugs approved in children and adolescents for psychiatric indications in several countries. Methods: All psychopharmacological treatments used in child and adolescent psychiatry, approved by at least one regulatory agency from Switzerland, the United Kingdom, France, the European Union, or the United States, were considered. A comprehensive review of the summaries of product characteristics was performed. Results: A total of 143 psychotropic drugs were included: 47 anxiolytics/hypnotics, 45 antidepressants, 37 antipsychotics, 10 medications for attention-deficit/hyperactivity disorder (ADHD), and 4 mood stabilizers. Only a few of these drugs were approved for use in children or adolescents (38%) at least for a single psychiatric diagnosis in at least one country. The therapeutic class with the lowest rate of approved status was antidepressants (20%), followed by mood stabilizers (25%), anxiolytics/hypnotics (28%), antipsychotics (57%), and medications for ADHD (100%). Important differences in approved diagnoses, ages, and doses were observed between regulatory agencies. Tables presenting drugs for approved diagnoses based on age and regulatory agencies are presented in this article. Drugs classified by regulatory agencies, with complete data on diagnoses, ages, doses, pharmaceutical forms, and particular restrictions, are presented as Supplementary Material. Conclusion: This article provides an overview to prescribers with respect to the approved medications in children and adolescents in selected European countries and the United States.
Mots-clé
Adolescent, Anti-Anxiety Agents/therapeutic use, Anticonvulsants/therapeutic use, Antidepressive Agents/therapeutic use, Antimanic Agents/therapeutic use, Antipsychotic Agents/therapeutic use, Child, Drug Prescriptions, Humans, Hypnotics and Sedatives/therapeutic use, Pharmaceutical Preparations, Psychotropic Drugs/therapeutic use, United States, European countries, approved indications, children and adolescents, psychiatry, psychotropic drugs
Pubmed
Web of science
Création de la notice
12/02/2022 15:09
Dernière modification de la notice
27/04/2022 6:37
Données d'usage